Neisseria meningitidis is a major cause of bacterial meningitis worldwide, especially in Africa. The capsular polysaccharide is the main virulence factor and the target antigen for polysaccharide- and conjugate vaccines. Three tetravalent conjugate vaccines against serogroups A, C, Y and W have been licensed and the monovalent MenAfriVac® was introduced to address the high burden of serogroup A disease in the Meningitis Belt of sub-Saharan Africa. Three of these four vaccines are lyophilized due to the instability of the serogroup A antigen (MenA) in aqueous solution, resulting in a two vial presentation with concomitant additional costs for storage and distribution. Replacement of the saccharide ring oxygen with a methylene group is a prom...
A vaccine to prevent infections from the emerging Neisseria meningitidis X (MenX) is becoming an urg...
The capsular polysaccharide of E. coli K92 (K92P) contains elements in common with the capsular poly...
Despite the considerable progress toward the eradication of meningococcal disease with the introduct...
The capsular polysaccharide is the main virulence factor in meningococcus. The capsular polysacchari...
Vaccination is the most cost-effective way to control disease caused by encapsulated bacteria; the c...
Synthesis of Neisseria meningitidis serogroup A carba analogues as hydrolytically stable antigens fo...
Neisseria meningitidis type A (MenA) is a Gram-negative encapsulated bacterium that is a major cause...
<i>Neisseria meningitidis</i> type A (MenA) is a Gram-negative encapsulated bacterium that is a majo...
Neisseria meningitidis serogroup A (MenA) is an aerobic diplococcal Gram-negative bacterium responsi...
Neisseria meningitidis is a Gram-negative encapsulated bacterium that is a major cause of meningitis...
Licensed conjugate vaccines have proven to be highly effective in preventing bacterial disease. Cove...
Neisseria meningitidis is a leading cause of severe bacterial infections in infants and young childr...
Neisseria meningitidis type A (MenA) is a Gram-negative encapsulated bacterium that causes recurrent...
Meningococcal meningitis remains a substantial cause of mortality and morbidity worldwide. Until rec...
N. meningitidis type X (Men X), first described in the 1960s1, has been found to cause a few cases o...
A vaccine to prevent infections from the emerging Neisseria meningitidis X (MenX) is becoming an urg...
The capsular polysaccharide of E. coli K92 (K92P) contains elements in common with the capsular poly...
Despite the considerable progress toward the eradication of meningococcal disease with the introduct...
The capsular polysaccharide is the main virulence factor in meningococcus. The capsular polysacchari...
Vaccination is the most cost-effective way to control disease caused by encapsulated bacteria; the c...
Synthesis of Neisseria meningitidis serogroup A carba analogues as hydrolytically stable antigens fo...
Neisseria meningitidis type A (MenA) is a Gram-negative encapsulated bacterium that is a major cause...
<i>Neisseria meningitidis</i> type A (MenA) is a Gram-negative encapsulated bacterium that is a majo...
Neisseria meningitidis serogroup A (MenA) is an aerobic diplococcal Gram-negative bacterium responsi...
Neisseria meningitidis is a Gram-negative encapsulated bacterium that is a major cause of meningitis...
Licensed conjugate vaccines have proven to be highly effective in preventing bacterial disease. Cove...
Neisseria meningitidis is a leading cause of severe bacterial infections in infants and young childr...
Neisseria meningitidis type A (MenA) is a Gram-negative encapsulated bacterium that causes recurrent...
Meningococcal meningitis remains a substantial cause of mortality and morbidity worldwide. Until rec...
N. meningitidis type X (Men X), first described in the 1960s1, has been found to cause a few cases o...
A vaccine to prevent infections from the emerging Neisseria meningitidis X (MenX) is becoming an urg...
The capsular polysaccharide of E. coli K92 (K92P) contains elements in common with the capsular poly...
Despite the considerable progress toward the eradication of meningococcal disease with the introduct...